ESOPJun 11, 2026, 04:17 PM
BeOne Medicines Shareholders Approve 75.4M Share Increase for Equity Plans
AI Summary
BeOne Medicines Ltd. shareholders approved significant increases in authorized shares for its equity incentive plans at the Annual General Meeting on June 11, 2026. The 2016 Share Option and Incentive Plan saw an increase of 75,400,000 ordinary shares, and the 2018 Employee Share Purchase Plan increased by 3,250,000 ordinary shares. Additionally, four directors did not stand for re-election, and their terms concluded without any disagreement. Shareholders also approved the 2025 financial statements, appropriation of accumulated loss, and discharged the Board and Executive Management from liability.
Key Highlights
- Shareholders approved 75,400,000 additional ordinary shares for the 2016 Share Option and Incentive Plan.
- Shareholders approved 3,250,000 additional ordinary shares for the 2018 Employee Share Purchase Plan.
- Four directors (Michael Goller, Ranjeev Krishana, Corazon D. Sanders, Qingqing Yi) did not stand for re-election.
- The 2025 audited Swiss statutory financial statements were approved with 1,026,904,777 votes for.
- Appropriation of the 2025 accumulated loss was approved with 1,028,050,311 votes for.
- Discharge of Board and Executive Management from liability was approved with 816,696,880 votes for.
- A quorum was met with 1,061,026,909 ordinary shares (73.36%) represented at the meeting.
Price Impact
More from ONC